Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.

Hung-Chih HsuYu-Chun LiuChuang-Wei WangWen-Chi ChouYu-Jen HsuJy-Ming ChiangYung-Chang LinTsai-Sheng Yang

Published in: Cancer medicine (2019)

Our study demonstrated that first-line cetuximab therapy followed by third-line bevacizumab therapy was associated with favorable clinical outcomes as compared to the reverse sequence.

Keyphrases

metastatic colorectal cancer
wild type
stem cells
metabolic syndrome
adipose tissue
mesenchymal stem cells
bone marrow
weight loss
rectal cancer